Key result
Aspirin evaluated for primary prevention of cardiovascular events in patients with elevated Lp(a).
Why the study?
Does Aspirin prevent Cardiovascular events in Patients with elevated Lipoprotein(a)?
Meta-Analysis
Does Aspirin prevent Cardiovascular events in Patients with elevated Lipoprotein(a)?
This is a correction notice clarifying the exclusion of the Cardiovascular Health Study (CHS) cohort from the meta-analysis due to incompatible Lp(a) measurement assays.
Answers are grounded in this paper and cite their sources.
May support aspirin in primary prevention for elevated Lp(a); strengthens evidence after excluding incompatible assay data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Caldeira et al. (2026) conducted a meta-analysis in Elevated Lipoprotein(a). Aspirin was evaluated. Aspirin's impact on primary prevention of cardiovascular events in patients with elevated Lp(a) was evaluated in a meta-analysis that excluded the Cardiovascular Health Study due to incompatible assays.
Synapse has enriched 10 related papers. Consider them for comparative context: